Has the European union achieved a single pharmaceutical market?
Tóm tắt
This paper explores price differences in the European Union (EU) pharmaceutical market, the EU’s fifth largest industry. With the aim of enhancing quality of life along with industry competitiveness and R&D capability, many EU directives have been adopted to achieve a single EU-wide pharmaceutical market. Using annual 1994–2003 data on prices of molecules that treat cardiovascular disease, we examine whether drug price dispersion has indeed decreased across five EU countries. Hedonic regressions show that over time, cross-country price differences between Germany and three of the four other EU sample countries, France, Italy and Spain, have declined, with relative prices in all three as well as the fourth country, UK, rising during the period. We interpret this as evidence that the EU has come closer to achieving a single pharmaceutical market in response to increasing European Commission coordination efforts.
Tài liệu tham khảo
Augurzky B., Gohlmann S., Greb S., Wasem J. (2009) Effects of the German reference drug program on ex-factory prices of prescription drugs: A panel data approach. Health Economics 18(4): 421–436
Barry, M., Bruzzone, M., DeJoncheere, K., Folino-Gallo, P., Rosian, I., Schroder, H., et al. (2004). Price indicators-the library of European Union pharmaceutical indicators. EURO-MED-STAT Group.
Berndt E.R. (2000) Editorial: International comparison of pharmaceutical prices? What do we know, and what does it mean?. Journal of Health Economics 19: 283–287
Berndt E.R., Bir A., Busch S.H., Frank R.G., Normand S.L.T. (2002) The medical treatment of depression, 1991–1996: Productive inefficiency, expected outcome variations, and price indexes. Journal of Health Economics 21: 373–396
Brekke K.R., Konigbauer I., Straume O.R. (2007) Reference pricing of pharmaceuticals. Journal of Health Economics 26: 613–642
Busse R., Schreyogg J., Klauss-Dirk H. (2005) Regulation of pharmaceutical markets in Germany: Improving efficiency and controlling expenditures?. International Journal of Health Planning and Management 20: 329–349
Capri, S., & Levaggi, R. (2005). Social science research network: Working paper series. International price regulations in the pharmaceutical sector: A common model to sharing cost and benefits. http://papers.ssrn.com.
DAFFE/CLP. (2000). Directorate for Financial, Fiscal and Enterprise Affairs, 29.
Danzon P.M. (1999) Price comparisons for pharmaceuticals: A review of U.S. and cross-national studies. The AEI Press, Washington
Danzon P.M., Chao L.W. (2000) Cross-national price differences for pharmaceuticals: How large, and why?. Journal of Health Economics 19: 159–195
Danzon, P. M., & Furukawa, M. F. (2006). Prices and availability of pharmaceuticals: Evidence from nine countries. Health Affairs, 25(5), 1353–1362.
Darba J., Rovira J. (1998) Parallel imports of pharmaceuticals in the European Union. Pharmacoeconomics 14(1): 129–136
Dickson, M., & Jacobzone, S. (2003). Pharmaceutical use and expenditure for cardiovascular disease and stroke: A study of 12 OECD countries. OECD Health Working Papers, DELSA/ELSA/WD/HEA, 1.
Drummond M.F. (2003) Will There ever be a European drug pricing and reimbursement agency?. The European Journal of Health Economics 4: 67–69
EFPIA. (2005). The pharmaceutical industry in figures. European Federation of Pharmaceutical Industries and Associations, Key Data: 2005 update, pp. 1–27.
Ellison S.F., Cockburn I., Griliches Z., Hausman J. (1997) Characteristics of demand for pharmaceutical products: An examination of four cephalosporins. The RAND Journal of Economics 28(3): 426–446
European Commission. (1998). The single market in pharmaceuticals. http://europa.eu.int/scadplus/leg/en/lvb/l21227.htm. Accessed February 2009.
Ganslandt M., Maskus K. (2004) Parallel imports and the pricing of pharmaceutical products: Evidence from the European Union. Journal of Health Economics 23: 1035–1057
Goldberg P. K., Verboven F. (2004) Cross-country price dispersion in the euro era: A case study of the European car market. Economic Policy, 19: 483–521
Hellerstein J. (1998) The importance of the physician in the generic versus trade-name prescription decision. The RAND Journal of Economics 29(1): 108–136
IMS. (2005). IMS midas quantum—data elements, measures and statistics.
Kanavos, P. (2001). Overview of pharmaceutical pricing and reimbursement regulation in Europe. Communication of the European communities, Dg- Enterprise. http://www.pharmacos.eudra.orf/F3/g10/docs/synthesis.pdf, Accessed April 2005.
Kravis I.B., Lipsey R.E. (1969) International price comparisons by regression methods. International Economic Review 10(2): 233–246
Mossialos, E., Mrazek, M., & Wally, T. (Eds.). (2004). Regulating pharmaceuticals in Europe: Striving for efficiency, equity and quality: European observatory on health systems and policies series. Open University Press.
Mrazek M. (2002) Comparative approaches to pharmaceutical price regulation in the European Union. Croatian Medical Journal 43(4): 453–461
Oaxaca R. (1973) Male-female wage differentials in urban labor markets. International Economic Review 14: 693–709
OECD. (2000). Competition and regulation issues in the pharmaceutical industry. Committee on Competition Law and Policy.
OECD Health Data. (2003). A comparative analysis of 30 countries.
Pammolli, F., Riccaboni, M., & Magazzini, L. (2004). European competitiveness in pharmaceuticals.
Pavcnik N. (2002) Do pharmaceutical prices respond to potential patient out-of-pocket expenses?. RAND Journal of Economics 33(3): 469–487
Scherer F.M. (1993) Pricing, profits and technological progress in the pharmaceutical industry. The Journal of Economic Perspectives 7(3): 97–115
Scherer F. M. (2000) Handbook of Health Economics (Vol. 1). Elsevier, Amsterdam
Seget, S. (2003). Pharmaceutical pricing strategies: Optimizing returns throughout R&D and marketing. Reuters Business Insight—Healthcare.
Sirmans G.S., Macpherson D.A., Zietz E.N. (2005) The composition of hedonic pricing models. Journal of Real Estate Literature 13(1): 3–43
The Association of the British Pharmaceutical Industry. (2007). Parallel trade in medicines.
Towse A. (1998) The pros and cons of a single “euro-price” for drugs. Pharmacoeconomics 13(3): 271–276